# Clene Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Clene Inc.).

## Overview

Clene Inc. is a U.S.-based pharmaceutical preparations company that also sells dietary mineral supplements through its subsidiary and commercial partners. The company’s reported revenue is currently small and comes mainly from sales of Zinc Factor, Gold Factor, and rMetx ZnAg Immune Boost, while most of its resources remain focused on research and development of drug candidates.

## Products & services

• rMetx ZnAg Immune Boost dietary mineral supplement
• Zinc Factor™ sold through 4Life supply agreement
• Gold Factor™ dietary mineral supplement
• Royalty revenue from Gold Factor license with 4Life
• Research and development of drug candidates

- **Dietary mineral supplements** (100%) — Aqueous zinc-silver and gold mineral supplement products sold directly or through 4Life.
- **Royalty revenue** (0%) — License-based royalties tied to Gold Factor sales under an exclusive agreement with 4Life.
- **Drug candidate development** (0%) — Research and development programs aimed at advancing Clene’s therapeutic pipeline.

- rMetx ZnAg Immune Boost dietary mineral supplement
- Zinc Factor™ sold through 4Life supply agreement
- Gold Factor™ dietary mineral supplement
- Royalty revenue from Gold Factor license with 4Life
- Research and development of drug candidates

## Customers

Clene sells its supplement products through a mix of direct subsidiary sales and a commercial supply/license relationship with 4Life, which appears to be the key channel partner. The customer base is therefore concentrated in a small number of commercial counterparties rather than broad retail distribution. The company’s R&D activity is aimed at future pharmaceutical customers and regulators, but current monetization is still centered on supplement products and royalties.

- **4Life commercial partner** (primary) — Buys Zinc Factor and Gold Factor under supply and license arrangements and drives most current product and royalty revenue.
- **Direct supplement buyers** (secondary) — Purchasers of rMetx ZnAg Immune Boost through Clene’s wholly owned subsidiary.
- **Future pharmaceutical end markets** (emerging) — Potential future patients, prescribers, and healthcare systems for Clene’s drug candidates.

- 4Life buys Zinc Factor and Gold Factor under supply agreements
- Royalty income depends on 4Life sales of Gold Factor
- dOrbital sells rMetx ZnAg Immune Boost as a subsidiary product
- Current revenue is concentrated in a few commercial counterparties
- Future drug candidates target healthcare and regulatory markets

## Geography

Clene is incorporated in Delaware and operates with subsidiaries in Australia and the Netherlands, reflecting a small international operating footprint. The reports do not disclose country-level revenue, so the business appears operationally global but commercially concentrated in a limited number of partner relationships. Geography matters mainly through tax credits in Australia, foreign subsidiary structure, and the company’s U.S. capital markets exposure on Nasdaq.

- Headquartered and incorporated in the United States
- Subsidiaries in Australia and the Netherlands support operations
- No country-level revenue disclosure was provided in the excerpts
- Australia generated R&D tax credits, not operating revenue
- Nasdaq listing creates U.S. capital market exposure

## Strategy

Clene’s near-term strategy is to preserve liquidity while continuing to develop its drug candidates and maintain limited supplement commercialization. Management is explicitly pursuing additional capital through equity, debt, licensing, collaboration, and ATM financing, while also cutting costs and slowing some R&D and commercialization work. The company’s strategic challenge is to bridge from a small, partner-driven supplement revenue base to a sustainable biotech platform.

- **Liquidity preservation and financing** (short-term) — The company has recurring losses and substantial doubt about going concern, so funding is essential to continue operations.
- **Cost reduction** (short-term) — Lowering cash burn extends runway while the company seeks external capital and advances its pipeline.
- **Pipeline development** (medium-term) — Long-term value depends on converting R&D into viable therapeutic products beyond the current supplement business.

- Raise additional capital through equity, debt, and partnerships
- Use ATM and warrant exercises to support liquidity
- Reduce R&D and commercialization spend to conserve cash
- Maintain limited supplement revenue while advancing pipeline
- Seek licensing or collaboration deals to fund development

## Risks

Clene faces acute financing and listing risk because it has sustained losses, negative operating cash flow, and a Nasdaq MVLS deficiency notice. Its current revenue base is small and concentrated in a few supplement-related agreements, so any disruption in partner purchases or commercialization could materially affect results. As a development-stage biotech, it also carries typical clinical, regulatory, and execution risk, while fair-value and convertible-instrument accounting can create volatility in reported earnings.

- **Nasdaq delisting risk** [high] — The company received a notice that its market value of listed securities was below the minimum requirement and may be delisted if it does not regain compliance.
- **Going concern and liquidity risk** [critical] — Management states it has incurred significant losses and expects additional losses, with plans dependent on raising new capital.
- **Customer and partner concentration** [high] — Current revenue depends heavily on 4Life-related supply and license arrangements and timing of purchases.
- **Development and regulatory execution risk** [high] — Future value depends on advancing drug candidates through research, development, and eventual commercialization.

- Nasdaq listing compliance risk due to low market value of listed securities
- Going concern risk from recurring losses and negative cash flow
- Revenue concentration in a small number of supplement agreements
- R&D and commercialization delays can reduce future value creation
- Convertible notes and warrant valuations can create earnings volatility

## Accounting

Clene’s accounting is shaped by a small revenue base, heavy R&D spending, and significant use of fair-value and convertible-instrument estimates. Revenue is driven by timing of partner purchases and royalty receipts, so quarterly results can be uneven and sensitive to contract activity. The company also records derivative and warrant liabilities, contingent earn-out obligations, and a full valuation allowance on deferred tax assets, all of which can materially affect reported earnings and balance sheet presentation.

- **Revenue recognition for supply and royalty agreements** — Affects reported revenue and comparability across periods
- **Fair value of warrants and derivative liabilities** — Can materially affect net income without changing cash flow
- **Convertible notes and contingent earn-out liabilities** — Affects liabilities, interest/other income, and dilution analysis
- **Deferred tax asset valuation allowance** — Limits recognition of tax benefits and signals ongoing losses

- Revenue timing depends on partner purchases and royalty activity
- R&D expense is a major operating cost and can swing with program timing
- Convertible notes are measured at amortized cost and may include embedded features
- Warrant and derivative fair values can create non-cash earnings volatility
- Full valuation allowance reflects uncertainty over deferred tax asset realization

---

*Last updated: 2026-04-28T19:58:17.976723+00:00*